$RENB
RENOVARO INC.

2023 Q1 Form 10-K Financial Statement

#000173112223000271 Filed on February 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.796M $3.160M $2.790M
YoY Change 36.04% 52.02% 43.84%
% of Gross Profit
Research & Development $239.1K $1.768M $1.212M
YoY Change -80.28% -85.36% 12.26%
% of Gross Profit
Depreciation & Amortization $28.24K $28.33K $31.72K
YoY Change -10.96% -15.51% 5.73%
% of Gross Profit
Operating Expenses $4.063M $4.956M $4.035M
YoY Change 0.72% -65.06% 31.85%
Operating Profit -$4.063M -$4.035M
YoY Change 0.72% 31.85%
Interest Expense $122.3K $4.630K -$87.92K
YoY Change -239.09% -104.96% -12.08%
% of Operating Profit
Other Income/Expense, Net -$264.9K $7.968M -$2.079M
YoY Change -87.26% -358.15% 136.25%
Pretax Income -$4.328M -$90.24M -$6.201M
YoY Change -30.21% 419.69% 53.88%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.328M -$90.24M -$6.201M
YoY Change -30.21% 419.71% 53.88%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08
Diluted Earnings Per Share -$0.08 -$1.71 -$117.8K
COMMON SHARES
Basic Shares Outstanding 55.71M shares
Diluted Shares Outstanding 55.97M shares

Balance Sheet

Concept 2023 Q1 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.948M $9.172M $11.15M
YoY Change -73.56% -55.61% 147.8%
Cash & Equivalents $2.948M $9.172M $11.15M
Short-Term Investments
Other Short-Term Assets $978.9K $393.0K $544.7K
YoY Change 79.7% 68.71% 36.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.927M $9.565M $11.70M
YoY Change -66.42% -54.23% 138.69%
LONG-TERM ASSETS
Property, Plant & Equipment $529.3K $586.5K $1.869M
YoY Change -71.68% -72.79% -15.06%
Goodwill $11.64M $11.64M
YoY Change 0.0%
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $74.27M $74.48M $21.74K
YoY Change 341549.26% 354909.48%
Total Long-Term Assets $74.80M $75.07M $168.4M
YoY Change -55.58% -55.5% -0.23%
TOTAL ASSETS
Total Short-Term Assets $3.927M $9.565M $11.70M
Total Long-Term Assets $74.80M $75.07M $168.4M
Total Assets $78.73M $84.63M $180.1M
YoY Change -56.29% -55.36% 3.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.471M $1.402M $487.0K
YoY Change 818.1% 337.32% -2.6%
Accrued Expenses $593.7K $1.031M $745.0K
YoY Change -20.3% -30.06% 24.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $6.001M $1.200M $4.802M
YoY Change 24.97%
Total Short-Term Liabilities $11.77M $6.451M $7.512M
YoY Change 56.73% 242.06% 436.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.577M $0.00
YoY Change -20.8% -100.0%
Other Long-Term Liabilities $829.2K $166.6K $11.35M
YoY Change -92.69% -97.71% 163.87%
Total Long-Term Liabilities $829.2K $5.563M $11.35M
YoY Change -92.69% -57.39% 13.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.77M $6.451M $7.512M
Total Long-Term Liabilities $829.2K $5.563M $11.35M
Total Liabilities $12.60M $12.01M $18.86M
YoY Change -33.17% -19.6% 65.42%
SHAREHOLDERS EQUITY
Retained Earnings -$220.8M -$204.3M
YoY Change 124.77%
Common Stock $5.800K $5.302K
YoY Change 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.13M $72.62M $161.2M
YoY Change
Total Liabilities & Shareholders Equity $78.73M $84.63M $180.1M
YoY Change -56.29% -55.36% 3.68%

Cashflow Statement

Concept 2023 Q1 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.328M -$90.24M -$6.201M
YoY Change -30.21% 419.71% 53.88%
Depreciation, Depletion And Amortization $28.24K $28.33K $31.72K
YoY Change -10.96% -15.51% 5.73%
Cash From Operating Activities -$3.308M -$3.050M -$2.785M
YoY Change 18.78% -76.59% 19.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.109M 1.070M 229.5K
YoY Change 818.67% -96.34% -93.33%
NET CHANGE
Cash From Operating Activities -3.308M -3.050M -2.785M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 2.109M 1.070M 229.5K
Net Change In Cash -1.199M -1.980M -2.555M
YoY Change -53.07% -112.28% -330.2%
FREE CASH FLOW
Cash From Operating Activities -$3.308M -$3.050M -$2.785M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.308M -$3.050M -$2.785M
YoY Change 18.78% -76.52% 19.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001527728
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q2 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
usd
CY2021Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
usd
CY2022Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2021 enob Issuance Of Commitment Shares Related To Lpc Purchase Agreement Value
IssuanceOfCommitmentSharesRelatedToLpcPurchaseAgreementValue
usd
CY2021 enob Shares Issued For Fully Vested Rsus
SharesIssuedForFullyVestedRsus
usd
CY2021 enob Indefinite Life Intangible Assets Impairment Charge
IndefiniteLifeIntangibleAssetsImpairmentCharge
usd
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
usd
CY2022 enob Proceeds From Direct Offering Net Of Issuance Costs
ProceedsFromDirectOfferingNetOfIssuanceCosts
usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
usd
CY2021 us-gaap Sublease Income
SubleaseIncome
usd
CY2022Q2 enob Change In Tax Rate
ChangeInTaxRate
usd
CY2021Q2 enob Change In Tax Rate
ChangeInTaxRate
usd
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
usd
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2022 enob Deferred Income Tax Expense Change In Tax Rate
DeferredIncomeTaxExpenseChangeInTaxRate
usd
CY2021 enob Deferred Income Tax Expense Change In Tax Rate
DeferredIncomeTaxExpenseChangeInTaxRate
usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-54478
CY2022 dei Entity Registrant Name
EntityRegistrantName
ENOCHIAN BIOSCIENCES INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2559340
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1927 Paseo Rancho Castillo
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90032
CY2022 dei City Area Code
CityAreaCode
(305)
CY2022 dei Local Phone Number
LocalPhoneNumber
918-1980
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
ENOB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Public Float
EntityPublicFloat
242848672 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55705521 shares
CY2022 dei Auditor Name
AuditorName
Sadler, Gibb & Associates, LLC
CY2022 dei Auditor Location
AuditorLocation
Draper, UT
CY2022 dei Auditor Firm
AuditorFirmId
3627
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20664410 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
392996 usd
CY2021Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
234583 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
9565138 usd
CY2021Q2 us-gaap Assets Current
AssetsCurrent
20898993 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586536 usd
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
719364 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44268 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
65906 usd
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
61571000 usd
CY2021Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
154824000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
11640000 usd
CY2021Q2 us-gaap Goodwill
Goodwill
11640000 usd
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
68635 usd
CY2021Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20984 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1157086 usd
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1435978 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74480989 usd
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167986868 usd
CY2022Q2 us-gaap Assets
Assets
84632663 usd
CY2021Q2 us-gaap Assets
Assets
189605225 usd
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1401867 usd
CY2021Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
320559 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1031462 usd
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1182323 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
220685 usd
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
90602 usd
CY2022Q2 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
2343318 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1200000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
253636 usd
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292409 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6450968 usd
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1885893 usd
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6037945 usd
CY2021Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1200000 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4577148 usd
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4579114 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
985699 usd
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1239334 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5562847 usd
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13056393 usd
CY2022Q2 us-gaap Liabilities
Liabilities
12013815 usd
CY2021Q2 us-gaap Liabilities
Liabilities
14942286 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53007082 shares
CY2022Q2 enob Escrow Shares Remaining
EscrowSharesRemaining
17414 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53007082 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52219661 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52219661 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5302 usd
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
5222 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276989179 usd
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
265580356 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204345197 usd
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90911805 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30436 usd
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10834 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
72618848 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
174662939 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84632663 usd
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189605225 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14329801 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7557990 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8372800 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15720262 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
93253000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123590 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123535 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
116079191 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
23401787 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-116079191 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-23401787 usd
CY2022 enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
2896627 usd
CY2021 enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-3048033 usd
CY2022 us-gaap Interest Expense
InterestExpense
372844 usd
CY2021 us-gaap Interest Expense
InterestExpense
379608 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
9 usd
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-32634 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
122041 usd
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
13179 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2645833 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3447096 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-113433358 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-26848883 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125276 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113433392 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26723607 usd
CY2022 enob Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
-2.16
CY2021 enob Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
-0.57
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-342 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-461310 usd
CY2022 enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
52528024 shares
CY2021 enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
47167262 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113433392 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26723607 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
19602 usd
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-30582 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113452994 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26693025 usd
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
166272261 usd
CY2021 enob Stock Issued Pursuant To Warrants Exercised Value
StockIssuedPursuantToWarrantsExercisedValue
82056 usd
CY2021 enob Contingent Share Issued Pursuant To Acquisition Agreement Value
ContingentShareIssuedPursuantToAcquisitionAgreementValue
192522 usd
CY2021 enob Shares Issued Pursuant To2021 Private Placement Value
SharesIssuedPursuantTo2021PrivatePlacementValue
5000800 usd
CY2021 enob Shares Issued In Lieu Of Interest On5 Million Notes Payable Extension Value
SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue
298178 usd
CY2021 enob Shares Issued Pursuant To Lpc Purchase Agreement
SharesIssuedPursuantToLpcPurchaseAgreement
1221350 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
26843999 usd
CY2021 enob Restricted Shares Converted To Shares For Services Rendered Value
RestrictedSharesConvertedToSharesForServicesRenderedValue
147000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1297798 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26723607 usd
CY2021 enob Foreign Currency Translation Loss Value
ForeignCurrencyTranslationLossValue
30582 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
174662939 usd
CY2022 enob Stock Issued Pursuant To Warrants Exercised Value
StockIssuedPursuantToWarrantsExercisedValue
130000 usd
CY2022 enob Contingent Share Issued Pursuant To Acquisition Agreement Value
ContingentShareIssuedPursuantToAcquisitionAgreementValue
798000 usd
CY2022 enob Shares Issued In Lieu Of Interest On5 Million Notes Payable Extension Value
SharesIssuedInLieuOfInterestOn5MillionNotesPayableExtensionValue
299178 usd
CY2022 enob Shares Issued Pursuant To Lpc Purchase Agreement
SharesIssuedPursuantToLpcPurchaseAgreement
4676399 usd
CY2022 enob Shares Issued For Fully Vested Rsus Value
SharesIssuedForFullyVestedRsusValue
9811 usd
CY2022 enob Shares Issued Pursuant To Options Exercised
SharesIssuedPursuantToOptionsExercised
4913 usd
CY2022 enob Restricted Shares Converted To Shares For Services Rendered Value
RestrictedSharesConvertedToSharesForServicesRenderedValue
252350 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5238252 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113433392 usd
CY2022 enob Foreign Currency Translation Loss Value
ForeignCurrencyTranslationLossValue
19602 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
72618848 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113433392 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26723607 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
123590 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
123534 usd
CY2022 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
2896627 usd
CY2021 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-3048033 usd
CY2022 enob Non Cash Compensation
NonCashCompensation
5490602 usd
CY2021 enob Non Cash Compensation
NonCashCompensation
1444798 usd
CY2022 enob Indefinite Life Intangible Assets Impairment Charge
IndefiniteLifeIntangibleAssetsImpairmentCharge
93253000 usd
CY2022 enob Amortization Of Discount On Note Payable
AmortizationOfDiscountOnNotePayable
-297212 usd
CY2021 enob Amortization Of Discount On Note Payable
AmortizationOfDiscountOnNotePayable
-296505 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-18168 usd
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1594 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-733739 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1081308 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-272318 usd
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
24056 usd
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
30004 usd
CY2022 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-13516 usd
CY2021 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-3440 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-139641 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
711687 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15732336 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20610723 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5156 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48892 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5156 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48892 usd
CY2022 enob Repayment Of Finance Agreement
RepaymentOfFinanceAgreement
560848 usd
CY2021 enob Repayment Of Finance Agreement
RepaymentOfFinanceAgreement
546651 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
130000 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
82056 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4913 usd
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5000800 usd
CY2021 enob Proceeds From Direct Offering Net Of Issuance Costs
ProceedsFromDirectOfferingNetOfIssuanceCosts
26843998 usd
CY2022 enob Proceeds From Lpc Equity Agreement
ProceedsFromLpcEquityAgreement
-4676399 usd
CY2021 enob Proceeds From Lpc Equity Agreement
ProceedsFromLpcEquityAgreement
-1221350 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4250464 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32601553 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5240 usd
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26111 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11492268 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11968049 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20664410 usd
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8696361 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20664410 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
79716 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
89224 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
34 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
37 usd
CY2022 enob Contingent Shares Issued Pursuant With Acquisition Agreement
ContingentSharesIssuedPursuantWithAcquisitionAgreement
798000 usd
CY2021 enob Contingent Shares Issued Pursuant With Acquisition Agreement
ContingentSharesIssuedPursuantWithAcquisitionAgreement
192522 usd
CY2022 enob Shares Issued In Lieu Of Interest Expense On Note Payable
SharesIssuedInLieuOfInterestExpenseOnNotePayable
-299178 usd
CY2021 enob Shares Issued In Lieu Of Interest Expense On Note Payable
SharesIssuedInLieuOfInterestExpenseOnNotePayable
-298178 usd
CY2022 enob Finance Agreement Entered Into In Exchange For Prepaid Assets
FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
666875 usd
CY2021 enob Finance Agreement Entered Into In Exchange For Prepaid Assets
FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
607250 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204345197 usd
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zN6Bj75F0Dnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_866_zzj8QeGs9Yi3">Reclassification</span></b> – Certain amounts in the prior period financial statements have been reclassified to conform to the current presentation. For the year ended June 30, 2021, we reclassified lab expenses of $<span id="xdx_903_eus-gaap--OtherGeneralAndAdministrativeExpense_c20200701__20210630_zA6mBdG4Kjl7" title="General and administrative expenses">182,140</span> from general and administrative expenses to research and development expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2021 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
182140 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zOVpsgrpXhRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86E_zbnutNloDb96">Accounting Estimates</span> </b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value of the contingent consideration liability, and the fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20664410 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
8805495 usd
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
20287212 usd
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
93253000 usd
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
61571000 usd
CY2021Q2 us-gaap Goodwill
Goodwill
11640000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8372800 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15720262 usd
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53007082 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52219661 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6807820 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4011653 shares
CY2022Q2 enob Common Stock Share Issued
CommonStockShareIssued
18081962 shares
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
21516000 usd
CY2022 enob Contingent Shares Issuable
ContingentSharesIssuable
1250000 shares
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.93
CY2022 enob Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Warrants Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWarrantsExercisePrice
1.30
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.090 pure
CY2022 enob Digital Call Rate
DigitalCallRate
0.97 pure
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113433392 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26723607 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204345197 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
944014 usd
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
980025 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
357478 usd
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
260661 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586536 usd
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
719364 usd
CY2022 us-gaap Depreciation
Depreciation
108595 usd
CY2021 us-gaap Depreciation
Depreciation
107647 usd
CY2022Q2 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
18168 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
18168 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44268 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
65906 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
14995 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
15888 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
65906 usd
CY2022 enob Period Change
PeriodChange
-14995 usd
CY2022 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-6643 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
44268 usd
CY2021Q2 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
166464000 usd
CY2022 enob Period Changes
PeriodChanges
-93253000 usd
CY2022Q2 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
73211000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
11067 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
11067 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
11067 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
11067 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44268 usd
CY2022 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
93253000 usd
CY2018Q4 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On November 13, 2017, the Registrant entered into a lease agreement for a term of five years and two months from November 1, 2017 with Plaza Medical Office Building, LLC, pursuant to which the Registrant agreed to lease approximately 2,325 rentable square feet (the “Plaza Lease”). The base rent for the Plaza Lease increased by 3% each year, and ranged from approximately $8,719 per month, for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022.
CY2019Q2 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 19, 2018, the Registrant entered into a lease agreement for a term of ten years from September 1, 2018 with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Registrant entered into an Addendum to the original lease agreement with an effective date of December 1, 2019, where it expanded the leased area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month as of the date of the amendment to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y11M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04 pure
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
298305 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
246004 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
253384 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
260985 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
313836 usd
CY2022Q2 enob Less Imputed Interest
LessImputedInterest
-133178 usd
CY2022Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1239336 usd
CY2022Q2 us-gaap Lessee Finance Sublease Residual Value Guarantee Description
LesseeFinanceSubleaseResidualValueGuaranteeDescription
On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022 for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,021.67 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
356073 usd
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
339094 usd
CY2022 us-gaap Sublease Income
SubleaseIncome
2962 usd
CY2022 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
353111 usd
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
339094 usd
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1200000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24181 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
72875 usd
CY2021 us-gaap Interest Expense Other
InterestExpenseOther
72967 usd
CY2021Q1 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
5000000 usd
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-11-30
CY2021Q1 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.06 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
74054 shares
CY2022Q2 enob Market Price
MarketPrice
298178 usd
CY2022Q1 us-gaap Shares Issued
SharesIssued
47115 shares
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
299178 usd
CY2021Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
666875 usd
CY2021Q4 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.0399 pure
CY2021Q4 enob Monthly Installments
MonthlyInstallments
56469 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
166625 usd
CY2022 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
5565 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
372844 usd
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
379608 usd
CY2022Q2 enob Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets
DeferredTaxAssetExcessTaxOverDepreciationFixedAssets
6406 usd
CY2021Q2 enob Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets
DeferredTaxAssetExcessTaxOverDepreciationFixedAssets
-6100 usd
CY2022Q2 enob Deferred Tax Asset Excess Tax Over Depreciation Patents
DeferredTaxAssetExcessTaxOverDepreciationPatents
5716 usd
CY2021Q2 enob Deferred Tax Asset Excess Tax Over Depreciation Patents
DeferredTaxAssetExcessTaxOverDepreciationPatents
5449 usd
CY2022Q2 enob Stockoptions Comp
StockoptionsComp
2831137 usd
CY2021Q2 enob Stockoptions Comp
StockoptionsComp
1192741 usd
CY2022Q2 enob Depreciation And Amortizations
DepreciationAndAmortizations
118020 usd
CY2021Q2 enob Depreciation And Amortizations
DepreciationAndAmortizations
81140 usd
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
71299011 usd
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13536884 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74260290 usd
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14810114 usd
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-59450176 usd
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-7070732 usd
CY2021 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
125276 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
34 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
59450176 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7070732 usd
CY2022 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
34 usd
CY2021 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
-125276 usd
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-125276 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-125276 usd
CY2022 enob Excess Tax Benefit Over Depreciation Fixed Assets
ExcessTaxBenefitOverDepreciationFixedAssets
6406 usd
CY2021 enob Excess Tax Benefit Over Depreciation Fixed Assets
ExcessTaxBenefitOverDepreciationFixedAssets
-6100 usd
CY2022 enob Excess Tax Benefit Over Depreciation Patents
ExcessTaxBenefitOverDepreciationPatents
5716 usd
CY2021 enob Excess Tax Benefit Over Depreciation Patents
ExcessTaxBenefitOverDepreciationPatents
5449 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2831137 usd
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1192741 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization
IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
118020 usd
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization
IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
81140 usd
CY2022 enob Income Tax Expense Benefit Operating Loss Carryforwards
IncomeTaxExpenseBenefitOperatingLossCarryforwards
13536884 usd
CY2021 enob Income Tax Expense Benefit Operating Loss Carryforwards
IncomeTaxExpenseBenefitOperatingLossCarryforwards
13536884 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
74260290 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14810114 usd
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53007082 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53007082 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52219661 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52219661 shares
CY2020Q3 us-gaap Purchase Obligation
PurchaseObligation
20000000 usd
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-08-01
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
47115 shares
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
299178 usd
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6266 shares
CY2021Q4 us-gaap Share Price
SharePrice
1.30
CY2021Q4 us-gaap Share Price
SharePrice
7.98
CY2021Q4 enob Noncash Transaction Impacted Stockholders Equity
NoncashTransactionImpactedStockholdersEquity
798000 usd
CY2021Q2 us-gaap Shares Issued
SharesIssued
5000 shares
CY2021Q2 us-gaap Shares Issued
SharesIssued
3866668 shares
CY2021Q2 us-gaap Share Price
SharePrice
7.50
CY2021Q2 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
26843998 usd
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2156012 usd
CY2021Q1 us-gaap Shares Issued
SharesIssued
35000 shares
CY2021Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
147000 usd
CY2021Q1 us-gaap Shares Issued
SharesIssued
74054 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
298178 usd
CY2020Q4 us-gaap Shares Issued
SharesIssued
63122 shares
CY2020Q4 enob Derivative Price Risk Option Strike Prices
DerivativePriceRiskOptionStrikePrices
1.30
CY2021Q4 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
82056 usd
CY2020Q4 us-gaap Shares Issued
SharesIssued
63122 shares
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
3.05
CY2020Q4 enob Non Cash Transaction Impacted On Stockholders Equity
NonCashTransactionImpactedOnStockholdersEquity
192522 usd
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17414 shares
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5490602 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1444798 usd
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6235329 usd
CY2019Q4 enob Upfront Payment
UpfrontPayment
10000000 usd
CY2019Q4 enob Payment For Expenditures
PaymentForExpenditures
760000 usd
CY2022 enob Prevention And Treatment Research
PreventionAndTreatmentResearch
150000 usd
CY2021 enob Prevention And Treatment Research
PreventionAndTreatmentResearch
10760000 usd
CY2021Q3 enob Initial Payment
InitialPayment
600000 usd
CY2021Q4 enob Paid Initial Payment
PaidInitialPayment
600000 usd
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17414 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis.
CY2022 us-gaap Related Party Costs
RelatedPartyCosts
4031500 usd
CY2021 us-gaap Related Party Costs
RelatedPartyCosts
13804000 usd

Files In Submission

Name View Source Status
enob-20220630_lab.xml Edgar Link unprocessable
0001731122-23-000271-index-headers.html Edgar Link pending
0001731122-23-000271-index.html Edgar Link pending
0001731122-23-000271.txt Edgar Link pending
0001731122-23-000271-xbrl.zip Edgar Link pending
e4443_10k.htm Edgar Link pending
e4443_ex21-1.htm Edgar Link pending
e4443_10k_htm.xml Edgar Link completed
e4443_ex23-1.htm Edgar Link pending
e4443_ex31-1.htm Edgar Link pending
e4443_ex31-2.htm Edgar Link pending
e4443_ex32-1.htm Edgar Link pending
e4443_ex32-2.htm Edgar Link pending
e4443_ex4-3.htm Edgar Link pending
enob-20220630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
enob-20220630_def.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
enob-20220630_cal.xml Edgar Link unprocessable
enob-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable